Compare Moody's Corporation (MCO) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moody's Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? Moody's Corporation trades at $493 (market cap $88.28B), while State Street SPDR S&P Biotech ETF trades at $151.8. The key difference: Moody's Corporation pays a 0.82% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Moody's Corporation nearer its low. Which is the better fit depends on your goals.
| MCO | XBI | |
|---|---|---|
Market Cap | $88.28B | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $539.61 | $164.28 |
52-Week Low | $412.23 | $85.16 |
Enterprise Value | $94.08B | — |
Dividend Yield | 0.82% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCO trades at $505.12, down 1.12% today, with a bullish technical signal from moving averages but overbought RSI readings near 76. The company shows strong fundamentals with Q1 2026 EPS beating estimates at $4.33, revenue growth to $7.72B in 2025, and robust profitability margins including a 31.69% net income margin. Recent news highlights AI integration initiatives and dividend sustainability, with a $1.03 dividend paid in June 2026.
Outlook remains positive given analyst consensus of $551.17 price target and 56% buy ratings, though valuation multiples like P/E of 36.65 pose risks if growth slows. Key risks include high debt levels and market sensitivity to credit cycles, but institutional support and recurring revenue model provide stability for long-term investors.
XBI, the SPDR S&P Biotech ETF, trades at $150.94, down 2.14% today amid a bearish technical signal. The ETF holds 155 biotech stocks equally weighted, offering high beta exposure. Recent news highlights a 17% monthly surge driven by AI drug discovery and M&A activity, though analyst consensus remains a lone Hold rating. Key support sits at $151 with resistance at $155.
Outlook hinges on biotech sector momentum from innovation and deal flow, but risks include volatility from small-cap holdings and regulatory uncertainty. The neutral sentiment and lack of fundamental ratios suggest investors await clearer earnings trends from underlying holdings for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
